Context Therapeutics Inc.(CNTX)

Description: Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.

---

Keywords: Cancer Biopharmaceutical Clinical Medicine Organ Systems Treatment Of Cancer Breast Cancer Antineoplastic Drugs Endocrine System Cancer Therapeutics Abortifacients Estranes Enones Progesterone Antiprogestogens

---

Home Page: www.contexttherapeutics.com

CNTX Technical Analysis

2001 Market Street
Philadelphia, PA 19103
United States
Phone: 267 225 7416

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)